3,4-dihydroxyphenylacetic acid has been researched along with Anochlesia in 56 studies
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.
(3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.
dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, in contrast to D2-selective antagonists, SCH39166 failed to increase plasma prolactin levels, did not block apomorphine-induced emesis in the dog and had minimal effects on the striatal levels of homovanillic acid or dihydroxyphenylacetic acid." | 3.67 | Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity. ( Barnett, A; Berger, JG; Chipkin, RE; Coffin, VL; Iorio, LC; McQuade, RD, 1988) |
| " Adult Wistar rats treated with CPZ (3 mg/kg/day, IP) were orally dosed with diclofenac and L-dopa/carbidopa for 21 days." | 1.51 | Neuroprotective effect of diclofenac on chlorpromazine induced catalepsy in rats. ( Khan, SS; Mirza, T; Naeem, S; Najam, R; Sikandar, B, 2019) |
| " VU0364770 showed efficacy alone or when administered in combination with L-DOPA or an adenosine 2A (A2A) receptor antagonist currently in clinical development (preladenant)." | 1.38 | The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease. ( Amalric, M; Blobaum, AL; Bode, J; Bridges, TM; Bubser, M; Conn, PJ; Daniels, JS; Dickerson, JW; Engers, DW; Hopkins, CR; Italiano, K; Jadhav, S; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Thompson, AD; Turle-Lorenzo, N, 2012) |
| "Rosiglitazone is a commonly prescribed insulin-sensitizing drug with a selective agonistic activity on the peroxisome proliferator-activated receptor-gamma (PPAR-gamma)." | 1.35 | PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease. ( Caboni, P; Carboni, E; Carta, AR; Frau, L; Garau, A; Ibba, M; Schintu, N, 2009) |
| " In electrophysiology studies, acute administration of FMPD selectively elevated the number of spontaneously active A10 (versus A9) dopamine neurons and chronic administration selectively decreased the number of spontaneously active A10 (versus A9) dopamine neurons." | 1.33 | Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine. ( Benvenga, MJ; Bymaster, FP; Calligaro, DO; Cohen, IR; Falcone, JF; Hemrick-Luecke, SK; Martin, FM; Moore, NA; Nelson, DL; Nisenbaum, LK; Rasmussen, K; Schaus, JM; Sundquist, SJ; Tupper, DE; Wiernicki, TR, 2005) |
| "Behaviour was evaluated by catalepsy tests and activity box." | 1.32 | Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. ( Schmidt, WJ; Srinivasan, J, 2003) |
| "Dopaminergic lesion produced catalepsy and hypoactivity." | 1.32 | Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease. ( Schmidt, WJ; Srinivasan, J, 2004) |
| "At low doses (+/-)-3b does not induce catalepsy, showing atypical antipsychotic properties similar to those of olanzapine." | 1.30 | New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. ( Bechelli, S; Cagnotto, A; Campiani, G; Ciani, SM; de Boer, P; Fiorini, I; Garofalo, A; Liao, Y; Mennini, T; Nacci, V; Tepper, PG; Wikström, H, 1998) |
| "Haloperidol-treated rats showed an increase of DA, DOPAC, and HVA overflow in the PFC and the NAC-C." | 1.29 | Dopamine increase in the prefrontal cortex correlates with reversal of haloperidol-induced catalepsy in rats. ( Baptista, T; Fernandez, R; Hernandez, L; Murzi, E; Tucci, S, 1994) |
| "Nicotine potentiated the catalepsy produced by haloperidol." | 1.29 | Nicotine potentiation of haloperidol-induced catalepsy: striatal mechanisms. ( Cahill, DW; el-Etri, MM; Emerich, DF; Norman, AB; Sanberg, PR; Shipley, MT; Zanol, MD, 1993) |
| "4." | 1.29 | Prevention by (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol. ( Andersen, HL; Kilpatrick, IC, 1996) |
| "The peptide-induced catalepsy occurred only at the dose of 100 ng/rat and hypomotility at both doses used." | 1.28 | Effects of calcitonin gene-related peptide on extrapyramidal motor system. ( Clementi, G; Drago, F; Fiore, CE; Grassi, M; Prato, A; Valerio, C, 1992) |
| "The catalepsy was significantly decreased by IP atropine." | 1.28 | Catalepsy induced by striatal acetylcholinesterase inhibition with fasciculin in rats. ( Bolioli, B; Castelló, ME; Dajas, F, 1992) |
| "Only buspirone (1." | 1.27 | Selective effects of buspirone and molindone on dopamine metabolism and function in the striatum and frontal cortex of the rat. ( McDonald, CC; McMillen, BA, 1983) |
| "Buspirone can potently increase dopaminergic impulse flow and metabolism, primarily due to inhibition of DA autoreceptors." | 1.27 | Comparative neuropharmacology of buspirone and MJ-13805, a potential anti-anxiety drug. ( Mattiace, LA; McMillen, BA, 1983) |
| "2-Br-LIS produced catalepsy in mice (ED50 3." | 1.27 | Central antidopaminergic properties of 2-bromolisuride, an analogue of the ergot dopamine agonist lisuride. ( Kehr, W; Sauer, G; Wachtel, H, 1983) |
| "All rats were tested for catalepsy and at the end of the last catalepsy test, striatal DOPAC, HVA and ACh were determined." | 1.27 | Conditional tolerance to haloperidol-induced catalepsy is not caused by striatal dopamine receptor supersensitivity. ( de Graaf, CJ; Korf, J, 1986) |
| "Concomitant with the onset of catalepsy there is a rise in HVA and DOPAC concentrations in whole and discrete parts of the brain (striatum, limbic system)." | 1.26 | Role of the dopaminergic system in the cataleptogenic action of bulbocapnine. ( Longo, VG; Massotti, M, 1979) |
| "Moreover, haloperidol did not produce catalepsy in these animals." | 1.26 | Intranigral kainic acid: evidence for nigral non-dopaminergic neurons controlling posture and behavior in a manner opposite to the dopaminergic ones. ( Concu, A; De Montis, GM; di Chiara, G; Olianas, MC; Tagliamonte, A, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 27 (48.21) | 18.7374 |
| 1990's | 15 (26.79) | 18.2507 |
| 2000's | 8 (14.29) | 29.6817 |
| 2010's | 6 (10.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Celorrio, M | 1 |
| Rojo-Bustamante, E | 1 |
| Fernández-Suárez, D | 1 |
| Sáez, E | 1 |
| Estella-Hermoso de Mendoza, A | 1 |
| Müller, CE | 1 |
| Ramírez, MJ | 1 |
| Oyarzábal, J | 1 |
| Franco, R | 1 |
| Aymerich, MS | 1 |
| Naeem, S | 1 |
| Najam, R | 1 |
| Khan, SS | 1 |
| Mirza, T | 1 |
| Sikandar, B | 1 |
| Konieczny, J | 1 |
| Czarnecka, A | 1 |
| Lenda, T | 1 |
| Kamińska, K | 2 |
| Lorenc-Koci, E | 1 |
| Aguiar, AS | 1 |
| Lopes, SC | 1 |
| Tristão, FS | 1 |
| Rial, D | 1 |
| de Oliveira, G | 1 |
| da Cunha, C | 1 |
| Raisman-Vozari, R | 1 |
| Prediger, RD | 1 |
| Schintu, N | 1 |
| Frau, L | 1 |
| Ibba, M | 1 |
| Caboni, P | 1 |
| Garau, A | 1 |
| Carboni, E | 1 |
| Carta, AR | 1 |
| Gołembiowska, K | 1 |
| Dziubina, A | 1 |
| Kowalska, M | 1 |
| Jones, CK | 1 |
| Bubser, M | 1 |
| Thompson, AD | 1 |
| Dickerson, JW | 1 |
| Turle-Lorenzo, N | 1 |
| Amalric, M | 1 |
| Blobaum, AL | 1 |
| Bridges, TM | 1 |
| Morrison, RD | 1 |
| Jadhav, S | 1 |
| Engers, DW | 1 |
| Italiano, K | 1 |
| Bode, J | 1 |
| Daniels, JS | 1 |
| Lindsley, CW | 1 |
| Hopkins, CR | 1 |
| Conn, PJ | 1 |
| Niswender, CM | 1 |
| Goldstein, N | 1 |
| Goldstein, R | 1 |
| Terterov, D | 1 |
| Kamensky, AA | 1 |
| Kovalev, GI | 1 |
| Zolotarev, YA | 1 |
| Avakyan, GN | 1 |
| Terterov, S | 1 |
| Srinivasan, J | 2 |
| Schmidt, WJ | 2 |
| Izzo, E | 1 |
| Sanna, PP | 1 |
| Koob, GF | 1 |
| Rasmussen, K | 1 |
| Benvenga, MJ | 1 |
| Bymaster, FP | 1 |
| Calligaro, DO | 1 |
| Cohen, IR | 1 |
| Falcone, JF | 1 |
| Hemrick-Luecke, SK | 1 |
| Martin, FM | 1 |
| Moore, NA | 1 |
| Nisenbaum, LK | 1 |
| Schaus, JM | 1 |
| Sundquist, SJ | 1 |
| Tupper, DE | 1 |
| Wiernicki, TR | 1 |
| Nelson, DL | 1 |
| Zetterström, T | 1 |
| Sharp, T | 1 |
| Ungerstedt, U | 1 |
| McMillen, BA | 3 |
| McDonald, CC | 1 |
| Mattiace, LA | 1 |
| Wachtel, H | 1 |
| Kehr, W | 1 |
| Sauer, G | 1 |
| De Simoni, MG | 1 |
| Guardabasso, V | 1 |
| Misterek, K | 1 |
| Algeri, S | 3 |
| Bowers, MB | 2 |
| Rozitis, A | 1 |
| Henderson, MG | 1 |
| Tucci, S | 1 |
| Fernandez, R | 1 |
| Baptista, T | 1 |
| Murzi, E | 1 |
| Hernandez, L | 1 |
| Sanberg, PR | 1 |
| Emerich, DF | 1 |
| el-Etri, MM | 1 |
| Shipley, MT | 1 |
| Zanol, MD | 1 |
| Cahill, DW | 1 |
| Norman, AB | 1 |
| Andersen, HL | 1 |
| Kilpatrick, IC | 2 |
| Horikawa, HP | 1 |
| Nakazato, T | 1 |
| Hikosaka, O | 1 |
| Fink-Jensen, A | 1 |
| Nielsen, EB | 1 |
| Hansen, L | 1 |
| Scheideler, MA | 1 |
| Campiani, G | 2 |
| Nacci, V | 2 |
| Bechelli, S | 1 |
| Ciani, SM | 1 |
| Garofalo, A | 1 |
| Fiorini, I | 1 |
| Wikström, H | 1 |
| de Boer, P | 1 |
| Liao, Y | 1 |
| Tepper, PG | 1 |
| Cagnotto, A | 2 |
| Mennini, T | 2 |
| Mohanakumar, KP | 1 |
| Muralikrishnan, D | 1 |
| Thomas, B | 1 |
| Butini, S | 1 |
| Gemma, S | 1 |
| Fattorusso, C | 1 |
| Catalanotti, B | 1 |
| Giorgi, G | 1 |
| Goegan, M | 1 |
| Minetti, P | 1 |
| Di Cesare, MA | 1 |
| Mastroianni, D | 1 |
| Scafetta, N | 1 |
| Galletti, B | 1 |
| Stasi, MA | 1 |
| Castorina, M | 1 |
| Pacifici, L | 1 |
| Ghirardi, O | 1 |
| Tinti, O | 1 |
| Carminati, P | 1 |
| Di Chiara, G | 2 |
| Vargiu, L | 1 |
| Porceddu, ML | 1 |
| Longoni, R | 1 |
| Mulas, A | 1 |
| Gessa, GL | 1 |
| Massotti, M | 2 |
| Longo, VG | 1 |
| Brunello, N | 1 |
| Calderini, G | 1 |
| Consolazione, A | 1 |
| Olianas, MC | 1 |
| De Montis, GM | 2 |
| Concu, A | 1 |
| Tagliamonte, A | 2 |
| Van Loon, GR | 2 |
| Kim, C | 2 |
| Bowers, SM | 1 |
| Waldmeier, PC | 1 |
| Delini-Stula, AA | 1 |
| De Souza, EB | 1 |
| Kaneko, M | 1 |
| Sato, K | 1 |
| Horikoshi, R | 1 |
| Yaginuma, M | 1 |
| Yaginuma, N | 1 |
| Shiragata, M | 1 |
| Kumashiro, H | 1 |
| Ono, N | 1 |
| Abiru, T | 1 |
| Sugiyama, K | 1 |
| Kamiya, H | 1 |
| Clementi, G | 1 |
| Grassi, M | 1 |
| Valerio, C | 1 |
| Prato, A | 1 |
| Fiore, CE | 1 |
| Drago, F | 1 |
| Castelló, ME | 1 |
| Bolioli, B | 1 |
| Dajas, F | 1 |
| Antelman, SM | 3 |
| Caggiula, AR | 1 |
| Kocan, D | 3 |
| Knopf, S | 3 |
| Meyer, D | 1 |
| Edwards, DJ | 3 |
| Barry, H | 1 |
| Essig, EC | 1 |
| Jolicoeur, FB | 1 |
| Rivest, R | 1 |
| St-Pierre, S | 1 |
| Drumheller, A | 1 |
| Lannes, B | 1 |
| Micheletti, G | 1 |
| Warter, JM | 1 |
| Kempf, E | 1 |
| Di Scala, G | 1 |
| Devoto, P | 1 |
| Meloni, D | 1 |
| Porcella, A | 1 |
| Saba, P | 1 |
| Yamada, K | 1 |
| Matsuo, N | 1 |
| Nagashima, M | 1 |
| Kumagai, M | 1 |
| Furukawa, T | 1 |
| Chipkin, RE | 1 |
| Iorio, LC | 1 |
| Coffin, VL | 1 |
| McQuade, RD | 1 |
| Berger, JG | 1 |
| Barnett, A | 1 |
| de Graaf, CJ | 1 |
| Korf, J | 1 |
| Kazandjian, A | 1 |
| Spyraki, C | 1 |
| Papadopoulou, Z | 1 |
| Sfikakis, A | 1 |
| Varonos, DD | 1 |
| Nowak, K | 1 |
| Welsch-Kunze, S | 1 |
| Kuschinsky, K | 1 |
| Olgiati, VR | 1 |
| Stramentinoli, G | 1 |
| Hillegaart, V | 2 |
| Ahlenius, S | 2 |
| Magnusson, O | 2 |
| Fowler, CJ | 2 |
| Perel, JM | 1 |
| Stiller, R | 1 |
| Thorell, G | 1 |
| Coyle, S | 1 |
| Napier, TC | 1 |
| Breese, GR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Ecopipam Treatment of Tourette Syndrome[NCT01244633] | Phase 1/Phase 2 | 18 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| A Safety and Pilot Activity Study of Ecopipam (PSYRX 101) in the Symptomatic Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease[NCT01065558] | Phase 1 | 5 participants (Actual) | Interventional | 2010-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Yale Global Tic Severity Score is a composite of subject reported severity of motor (range 0-25) and vocal (range 0-25) tics , as well as an impairment score (range 0-50). The outcome we are using is the Total Tic Severity score which is the sum of the motor and vocal tic severity scores (range 0-50). The higher the score on this scale, the more severe the symptoms. A positive drug effect is associated with a decrease from baseline. (NCT01244633)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Ecopipam | 25.3 |
Change in the self-injurious subscale of the Behavior Problems Inventory (BPI). the BPI is a well-validate test to evaluate the frequency and severity of a patient's self-injurious behavior. Values range from 0 to 50, and a low score means few/less severe behaviors (NCT01065558)
Timeframe: Screening visit and end of study (two weeks)
| Intervention | Change in BPI score (Mean) |
|---|---|
| Ecopipam Treated Patients | 22.5 |
This study's primary outcome is the safety of ecopipam in Lesch-Nyhan patients as measured by standard clinical laboratory tests. The patients will also be observed and questioned about other side effects, such as whether they feel more or less tired.Standard clinical laboratory tests for liver, kidney and blood function were conducted. The normal ranges for each of these tests were different and are too numerous to be individually listed here. However, if any individual value were to be either three-times greater or lesser than the upper or the lower limit of the test, then that value was considered to have been changed. (NCT01065558)
Timeframe: Two weeks
| Intervention | Participants (Number) |
|---|---|
| Ecopipam Treated Patients | 0 |
1 review available for 3,4-dihydroxyphenylacetic acid and Anochlesia
| Article | Year |
|---|---|
Effect of enkephalins on catecholamine metabolism in rat CNS.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Analgesics; Animals; Brain; Catalepsy; Catecholam | 1978 |
55 other studies available for 3,4-dihydroxyphenylacetic acid and Anochlesia
| Article | Year |
|---|---|
GPR55: A therapeutic target for Parkinson's disease?
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson | 2017 |
Neuroprotective effect of diclofenac on chlorpromazine induced catalepsy in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Carbidopa; Catalepsy; Chlorpromazine; Corpus Striatum; Dicl | 2019 |
Chronic L-DOPA treatment attenuates behavioral and biochemical deficits induced by unilateral lactacystin administration into the rat substantia nigra.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcysteine; Adrenergic Agents; Animals; Antiparkinson Agents; Ap | 2014 |
Exercise Improves Cognitive Impairment and Dopamine Metabolism in MPTP-Treated Mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Catale | 2016 |
PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catalepsy; CD11b Antigen; Chromatography, High Pressure Liq | 2009 |
Effect of adenosine A(2A) receptor antagonists on L-DOPA-induced hydroxyl radical formation in rat striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Area Under Curve; Benser | 2009 |
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Brain; Calcium Signaling | 2012 |
Blood-brain barrier unlocked.
Topics: 3,4-Dihydroxyphenylacetic Acid; Administration, Intranasal; Animals; Blood-Brain Barrier; Catalepsy; | 2012 |
Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Behavior, Animal; Benzylamines; Cataleps | 2003 |
Behavioral and neurochemical effects of noradrenergic depletions with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine in 6-hydroxydopamine-induced rat model of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Basal | 2004 |
Impairment of dopaminergic system function after chronic treatment with corticotropin-releasing factor.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Catalepsy; Corpus Striatum; Corticotropin | 2005 |
Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Catalep | 2005 |
Effect of neuroleptic drugs on striatal dopamine release and metabolism in the awake rat studied by intracerebral dialysis.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Dialysis; | 1984 |
Selective effects of buspirone and molindone on dopamine metabolism and function in the striatum and frontal cortex of the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Anxiety Agents; Buspirone; Catalepsy; Cerebral Cortex; | 1983 |
Comparative neuropharmacology of buspirone and MJ-13805, a potential anti-anxiety drug.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anti-Anxiety Agents; Apomorphine; Buspirone; Catalepsy; Cor | 1983 |
Central antidopaminergic properties of 2-bromolisuride, an analogue of the ergot dopamine agonist lisuride.
Topics: 3,4-Dihydroxyphenylacetic Acid; 5-Hydroxytryptophan; Animals; Body Temperature; Brain; Catalepsy; Ch | 1983 |
Similarities and differences between D-ALA2 MET5 enkephalin amide and morphine in the induction of tolerance to their effects on catalepsy and on dopamine metabolism in the rat brain.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Catalepsy; Corpus Striatum; Dopamine; Drug Tolerance | 1982 |
Dopamine metabolites and catalepsy after lithium and haloperidol.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Catalepsy; Dopamine; Haloperidol; Homovanillic Acid; | 1982 |
Changes in dopamine, serotonin and their metabolites in discrete brain areas of rat offspring after in utero exposure to cocaine or related drugs.
Topics: 3,4-Dihydroxyphenylacetic Acid; Aging; Amitriptyline; Amygdala; Analysis of Variance; Animals; Brain | 1993 |
Dopamine increase in the prefrontal cortex correlates with reversal of haloperidol-induced catalepsy in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catalepsy; Caudate Nucleus; Chromatography, High Pressure L | 1994 |
Nicotine potentiation of haloperidol-induced catalepsy: striatal mechanisms.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Catalepsy; Chromatography, High Pressure | 1993 |
Prevention by (+/-)-8-hydroxy-2-(di-n-propylamino)tetralin of both catalepsy and the rises in rat striatal dopamine metabolism caused by haloperidol.
Topics: 3,4-Dihydroxyphenylacetic Acid; 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Behavior, Animal; C | 1996 |
Duration of catalepsy correlates with increased intrastriatal sulpiride.
Topics: 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Catalepsy; Dopamine; Dopamine | 1997 |
Behavioral and neurochemical effects of the preferential dopamine D3 receptor agonist cis-8-OH-PBZI.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Uptake Inhibitors; Animals; Avoidance Learning; Behavior, | 1998 |
New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Brain; Catalepsy; Dopamine; Dopamine | 1998 |
Neuroprotection by sodium salicylate against 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine-induced neurotoxicity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Ani | 2000 |
Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Behavior, Animal; Brain; Catalepsy; C | 2002 |
Indirect activation of the DA system as a possible mechanism for the stimulatory effects of narcotic analgesics.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Analgesics, Opioid; Animals; Apomorphine; Catalep | 1977 |
Role of the dopaminergic system in the cataleptogenic action of bulbocapnine.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aporphines; Brain Chemistry; Catalepsy; Dopamine; Homovanil | 1979 |
Involvement of striatal dopamine, homovanillic acid and 3,4-dihydroxyphenylacetic acid in the hypothermia and catalepsy induced by haloperidol.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Body Temperature; Catalepsy; Corpus Stria | 1977 |
Intranigral kainic acid: evidence for nigral non-dopaminergic neurons controlling posture and behavior in a manner opposite to the dopaminergic ones.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Animals; Behavior, Animal; Catalepsy; Corpus Stri | 1978 |
Dopaminergic mediation of beta-endorphin-induced catalepsy.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Brain Chemistry; Catalepsy; Corpus Striatum; D | 1978 |
Catalepsy, DOPAC, and acetylcholine during chronic fluphenazine administration.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Animals; Brain; Catalepsy; Caudate Nucleus; Cerebral | 1978 |
Serotonin--dopamine interactions in the nigrostriatal system.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Catalepsy; Corpus Striatum; Dopamine; Drug Int | 1979 |
Alterations in brain dopamine and serotonin metabolism during the development of tolerance to human beta-endorphin in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analgesics; Animals; Body Temperature; Brain; Catalepsy; Dopamine; D | 1978 |
Effect of haloperidol on cyclic AMP and inositol trisphosphate in rat striatum in vivo.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catalepsy; Corpus Striatum; Cyclic AMP; Dopamine; Haloperid | 1992 |
Influences of cyclooxygenase inhibitors on the cataleptic behavior induced by haloperidol in mice.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Aspirin; Catalepsy; Corpus Striatum; Cyclooxygenase Inhibit | 1992 |
Effects of calcitonin gene-related peptide on extrapyramidal motor system.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Calcitonin Gene-Related Pept | 1992 |
Catalepsy induced by striatal acetylcholinesterase inhibition with fasciculin in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Atropine; Catalepsy; Cholinesterase Inhibitors; Corpus Stri | 1992 |
One experience with 'lower' or 'higher' intensity stressors, respectively enhances or diminishes responsiveness to haloperidol weeks later: implications for understanding drug variability.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Animals; Catalepsy; Corticosterone; Deoxygluco | 1991 |
Influence of acute and chronic haloperidol treatment on dopamine metabolism in the rat caudate-putamen, prefrontal cortex and amygdala.
Topics: 3,4-Dihydroxyphenylacetic Acid; Amygdala; Animals; Behavior, Animal; Brain Chemistry; Catalepsy; Cau | 1991 |
Antiparkinson-like effects of neurotensin in 6-hydroxydopamine lesioned rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Behavior, Animal; Brain Chemistry; Ca | 1991 |
Behavioural, pharmacological and biochemical effects of acute and chronic administration of ketamine in the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Behavior, Animal; Brain Chemistry; Catalepsy; | 1991 |
Resistance to extrapyramidal effects of opiates in rats chronically treated with SCH 23390.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Benzazepines; Catalepsy; Corpus Striatum; Drug Tolerance; M | 1989 |
Dopamine receptor blocking action of a dibenzothiepin derivative isofloxythepin in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Antipsychotic Agents; Catalepsy; Corpus Striatum; Dibenzoth | 1989 |
Anticonvulsant and other effects of diazepam grow with time after a single treatment.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Anticonvulsants; Antipsychotic Agents; Blepharoptosis; Brai | 1989 |
Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Avoid | 1988 |
Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Avoid | 1988 |
Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Avoid | 1988 |
Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenylyl Cyclases; Animals; Antipsychotic Agents; Apomorphine; Avoid | 1988 |
Conditional tolerance to haloperidol-induced catalepsy is not caused by striatal dopamine receptor supersensitivity.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acetylcholine; Animals; Catalepsy; Corpus Striatum; Drug Tolerance; | 1986 |
Behavioural and biochemical effects of haloperidol during the oestrous cycle of the rat.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Catalepsy; Dopamine; Estrus; Female; Halop | 1988 |
Conditioned tolerance to haloperidol- and droperidol-induced catalepsy.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Apomorphine; Brain; Catalepsy; Conditioning, Psychological; | 1988 |
Biochemical and behavioural indices of striatal dopaminergic activity after 6-methyltetrahydropterin.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Behavior, Animal; Catalepsy; Chromatography, High Pressure | 1987 |
Repeated testing of rats markedly enhances the duration of effects induced by haloperidol on treadmill locomotion, catalepsy, and a conditioned avoidance response.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Avoidance Learning; Catalepsy; Conditioning, Classical; Cor | 1987 |
Behavioral effects of a single neuroleptic treatment grow with the passage of time.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain; Catalepsy; Corpus Striatum; Dopamine; Fluphenazine; | 1986 |
Suppression of exploratory locomotor activity and increase in dopamine turnover following the local application of cis-flupenthixol into limbic projection areas of the rat striatum.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Catalepsy; Corpus Striatum; Dopamine; Exploratory Behavior; | 1987 |
Ontogeny of tolerance to haloperidol: behavioral and biochemical measures.
Topics: 3,4-Dihydroxyphenylacetic Acid; Age Factors; Animals; Brain Chemistry; Catalepsy; Corpus Striatum; D | 1985 |